Peter A. Thompson
CIK 1357522 · Interim Chief Exec Officer · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.50B
Companies
15
Total Filings
128
Lifetime Open-Market Net
$70.98M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SION | Director | 2,469,959 | $46.55 | $114.98M | -$45.77M | 13 | 2026-07-09 |
| SPRY | Director | 269,323 | $5.67 | $1.53M | -$9.49M | 7 | 2026-06-26 |
| EWTX | Director | 443,792 | $40.35 | $17.91M | $26.74M | 10 | 2026-06-17 |
| CRVS | Director | 8,684,091 | $13.31 | $115.59M | $10.58M | 30 | 2026-06-15 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 0 | $64.97 | $0 | -$25.72M | 14 | 2024-05-20 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 327,852 | $4.91 | $1.61M | $30.00M | 3 | 2022-06-21 |
| JANX | Director | 231,098 | $15.00 | $3.47M | $1.41M | 6 | 2022-06-16 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 952,377 | $5.87 | $5.59M | $25.00M | 4 | 2022-06-13 |
| PMVP | Director | 114,039 | $1.10 | $125.4K | $17.10M | 2 | 2021-06-09 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 12,940,111 | — | — | $15.00M | 2 | 2020-06-19 |
| Synthorx, Inc. (THOR) Delisted | Director | 0 | — | — | $15.00M | 4 | 2020-01-24 |
| ASND | Director | 4,902,910 | $254.44 | $1.25B | $8.09M | 8 | 2018-06-06 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,989,949 | — | — | $2.98M | 1 | 2015-07-21 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 2 | 2012-05-10 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | President and CEO | 386,419 | — | — | $50.3K | 5 | 2009-08-28 |
Recent Filings · Page 2 of 13
128 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-04 | SION | Sell (S) | −30,953 | -$1.38M | EDGAR |
| 2026-01-30 | CRVS | Exer (M) | +210,000 | $1.12M | EDGAR |
| 2025-12-29 | SION | Sell (S) | −33,356 | -$1.49M | EDGAR |
| 2025-12-19 | SION | Sell (S) | −1,875 | -$83.4K | EDGAR |
| 2025-11-26 | SION | Sell (S) | −108,073 | -$4.81M | EDGAR |
| 2025-07-01 | CRVS | Mixed | +221,352 | -$0 | EDGAR |
| 2025-06-27 | SPRY | Grant (A) | — | $0 | EDGAR |
| 2025-06-18 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | SION | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | CRVS | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.